Eli Lilly and Co. (LLY) and Nektar Therapeutics (NKTR) Monday announced a strategic collaboration to co-develop NKTR-358, an immunological therapy discovered by Nektar. The compound is intended to reat a number of autoimmune and other chronic inflammatory conditions.
from RTT - Earnings http://ift.tt/2uPiquO
via IFTTT
No comments:
Post a Comment